J Korean Med Sci.  2014 Oct;29(10):1331-1332. 10.3346/jkms.2014.29.10.1331.

Lesionalized Therapy beyond Personalized Therapy in Cancer Management

• Chung JK
• Kim MJ
• Youn H

• KMID: 2129621
• DOI: http://doi.org/10.3346/jkms.2014.29.10.1331

Abstract

No abstract available.

MeSH Terms

Fluorodeoxyglucose F18/diagnostic use
Genetic Variation
Humans
Individualized Medicine/*methods
Iodine Radioisotopes/*therapeutic use
Molecular Imaging/methods
Positron-Emission Tomography
Symporters/biosynthesis/*metabolism
Thyroid Neoplasms/*drug therapy/*genetics
Tumor Microenvironment
Fluorodeoxyglucose F18
Iodine Radioisotopes
Symporters

Reference

1. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19:1423–1437.

2. Zardavas D, Baselga J, Piccart M. Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol. 2013; 10:191–210.

3. Min JJ, Chung JK, Lee YJ, Jeong JM, Lee DS, Jang JJ, Lee MC, Cho BY. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med. 2001; 28:639–645.

4. So YK, Son YI, Baek CH, Jeong HS, Chung MK, Ko YH. Expression of sodium-iodide symporter and TSH receptor in subclinical metastatic lymph nodes of papillary thyroid microcarcinoma. Ann Surg Oncol. 2012; 19:990–995.

5. Kim S, Chung JK, Min HS, Kang JH, Park DJ, Jeong JM, Lee DS, Park SH, Cho BY, Lee S, et al. Expression patterns of glucose transporter-1 gene and thyroid specific genes in human papillary thyroid carcinoma. Nucl Med Mol Imaging. 2014; 48:91–97.

6. Lee J, Nah KY, Kim RM, Oh YJ, An YS, Yoon JK, An GI, Choi TH, Cheon GJ, Soh EY, et al. Effectiveness of [(124)I]-PET/CT and [(18)F]-FDG-PET/CT for localizing recurrence in patients with differentiated thyroid carcinoma. J Korean Med Sci. 2012; 27:1019–1026.